Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Overall Survival
100%
Progression-free Survival
100%
Distant Failure
100%
Time to Progression
100%
Chemoradiation
100%
Erlotinib
100%
Stage III Non-small Cell Lung Cancer
100%
Non-small Cell Lung Cancer (NSCLC)
66%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
66%
Previously Untreated
66%
Disease Control
66%
EGFR mutation
66%
Systemic Therapy
33%
Chemotherapy
33%
Median Overall Survival
33%
Adenocarcinoma
33%
Carboplatin
33%
Paclitaxel
33%
Complete Response
33%
Never-smokers
33%
Phase II Trial
33%
Former Smokers
33%
5-year Survival
33%
Median Time
33%
Concurrent Chemoradiotherapy
33%
Intensity-modulated Radiation Therapy
33%
Received Intensity
33%
Locally Advanced
33%
Mutation Status
33%
Overall Survival Time
33%
Response Control
33%
Area under the Curve
33%
Toxicity Response
33%
Receptor Status
33%
Toxicity Control
33%
Met Expectations
33%
Carboplatin/paclitaxel
33%
Patient Median
33%
Epidermal Growth Factor Receptor Inhibitors (EGFRI)
33%
Medicine and Dentistry
Overall Survival
100%
Progression Free Survival
100%
Chemoradiotherapy
100%
Non Small Cell Lung Cancer
100%
Erlotinib
100%
Epidermal Growth Factor Receptor
60%
Diseases
40%
Epidermal Growth Factor Receptor Kinase Inhibitor
40%
Paclitaxel
40%
Carboplatin
40%
Prevalence
20%
Systemic Therapy
20%
Survival Time
20%
Adenocarcinoma
20%
Survival Rate
20%
Arm
20%
Chemotherapy
20%
Intensity Modulated Radiation Therapy
20%
Area under the Curve
20%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
100%
Non Small Cell Lung Cancer
100%
Progression Free Survival
100%
Chemoradiation Therapy
100%
Erlotinib
100%
Epidermal Growth Factor Receptor
60%
Diseases
40%
Carboplatin
40%
Paclitaxel
40%
Epidermal Growth Factor Receptor Kinase Inhibitor
40%
Adenocarcinoma
20%
Survival Rate
20%
Prevalence
20%
Survival Time
20%
Chemotherapy Regimen
20%